Generic Product News (February 2016)

Pharmacy TimesFebruary 2016 Autoimmune Disorders
Volume 82
Issue 2

Read about the new generic products featured in February.

Camber Pharmaceuticals

Compare to: Zyvox (Pfizer)

Indication: Camber Pharmaceuticals has launched Linezolid Tablets, the generic equivalent to Zyvox, in a 600-mg tablet strength. The drug is indicated to treat several types of bacterial infections, including pneumonia, skin infections, and other antibiotic-resistant infections.

Dosage Form: Tablets: 600 mg

For More Information:

Norgestimate/Ethinyl Estradiol Tablets Marketed by: Teva Pharmaceuticals

Compare to: Ortho Tri-Cyclen Lo (Janssen Pharmaceuticals)

Indication: Teva Pharmaceutical Industries has launched Norgestimate/Ethinyl Estradiol Contraceptive Tablets, the generic equivalent to Janssen Pharmaceuticals’ Ortho Tri-Cyclen Lo. The oral contraceptive is available for women in a 28-day blister pack dispenser.

Dosage Form: 28-day blister pack

For More Information:

Clozapine Orally Disintegrating TabletsMarketed by: Mylan

Compare to: FazaClo (Jazz Pharmaceuticals)

Indication: Mylan has announced the launch of Clozapine Orally Disintegrating Tablets, the generic equivalent to Jazz Pharmaceuticals’ FazaClo, in 25- and 100-mg tablet strengths. The product is indicated to treat severely ill patients with schizophrenia who do not respond adequately to standard antipsychotic treatment.

Dosage Form: Tablets: 25 and 100 mg

For More Information:

Famotidine Tablets USP, 20 Mg and 40 MgMarketed by: Aurobindo Pharma Limited

Compare to: Pepcid (Valeant)

Indication: Aurobindo Pharma has received FDA approval for Famotidine Tablets USP, 20 mg and 40 mg, the therapeutic equivalent to Valeant Pharmaceuticals’ Pepcid. The product is indicated to treat duodenal ulcers, active benign gastric ulcers, gastroesophageal reflux disease, and pathological hypersecretory conditions.

Dosage Form: Tablets: 20 mg and 40 mg

For More Information:

Related Videos
Practice Pearl #1 Active Surveillance vs Treatment in Patients with NETs
© 2024 MJH Life Sciences

All rights reserved.